Craniometrix
Catch Alzheimer's 3x as accurately as a doctor & 10 years before symptoms.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | $6.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Craniometrix operates in the healthcare technology sector, focusing on early detection of cognitive impairments such as Alzheimer's disease. The company serves individuals concerned about their cognitive health, offering a proprietary 10-minute screening test that can be taken on a computer or tablet. Utilizing advanced artificial intelligence algorithms, Craniometrix analyzes over one million data points to assess the likelihood of cognitive decline. The results are reviewed by a human expert, who prepares a personalized report detailing the individual's risk. This early diagnosis tool is designed to be three times as accurate as current screening methods, providing significant value to users by enabling early intervention.
The business model is primarily direct-to-consumer, with revenue generated through the sale of screening tests. Craniometrix also aims to collaborate with healthcare providers and researchers to expand its market reach and application. The company operates in the digital health market, leveraging AI and machine learning technologies to offer innovative solutions for cognitive health assessment.
Keywords: AI, cognitive screening, Alzheimer's, early detection, personalized reports, healthcare technology, digital health, machine learning, cognitive impairment, direct-to-consumer.